{
    "Trade/Device Name(s)": [
        "VARIANTTM II Hemoglobin A1c Program",
        "VARIANTTM II \u03b2-thalassemia Short Program"
    ],
    "Submitter Information": "Bio-Rad Laboratories, Inc.",
    "510(k) Number": "K130860",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070452",
        "K063643"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "JPD"
    ],
    "Summary Letter Date": "March 21, 2013",
    "Summary Letter Received Date": "March 28, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7470",
        "21 CFR 864.7400"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay",
        "Hemoglobin A2 assay"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c",
        "Hemoglobin A2",
        "Hemoglobin F",
        "Abnormal hemoglobins"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VARIANT II Hemoglobin Testing System",
        "VARIANT II Chromatographic Station (VCS)",
        "VARIANT II Sampling Station (VSS)",
        "Personal computer with Clinical Data Management (CDM) Software"
    ],
    "Method(s)/Technology(ies)": [
        "Ion-exchange high-performance liquid chromatography (HPLC)"
    ],
    "Methodologies": [
        "Chromatographic separation",
        "Percent determination"
    ],
    "Submission Type(s)": [
        "Assay",
        "Software",
        "Analyzer",
        "Instrument",
        "Component",
        "Cartridge",
        "Calibrator",
        "Vial",
        "Buffer",
        "Diluent",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Bio-Rad VARIANT II Hemoglobin A1c Program and \u03b2-thalassemia Short Program, assays for hemoglobin A1c, A2, F, and abnormal hemoglobins using ion-exchange HPLC.",
    "Indications for Use Summary": "VARIANT II Hemoglobin A1c Program measures percent hemoglobin A1c for monitoring long-term glucose control in diabetes; \u03b2-thalassemia Short Program separates and quantifies hemoglobins A2 and F to aid in identification of abnormal hemoglobins and screening for \u03b2-thalassemia.",
    "fda_folder": "Hematology"
}